

Mahmoud El-Tamer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8265525/publications.pdf>

Version: 2024-02-01

48
papers

1,370
citations

430874

18
h-index

477307

29
g-index

48
all docs

48
docs citations

48
times ranked

1544
citing authors

#	ARTICLE	IF	CITATIONS
1	How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 3467-3474.	1.5	232
2	Skin Flap Necrosis After Mastectomy With Reconstruction: A Prospective Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 257-264.	1.5	121
3	A Consensus Definition and Classification System of Oncoplastic Surgery Developed by the American Society of Breast Surgeons. <i>Annals of Surgical Oncology</i> , 2019, 26, 3436-3444.	1.5	113
4	Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 22-27.	1.5	99
5	Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers. <i>Annals of Surgery</i> , 2017, 266, 457-462.	4.2	90
6	Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 523-537.	2.5	84
7	Selection Criteria for Postmastectomy Radiotherapy in T1-T2 Tumors with 1 to 3 Positive Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2013, 20, 3169-3174.	1.5	77
8	MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of the American College of Surgeons</i> , 2017, 225, 740-746.	0.5	77
9	A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy. <i>Breast Cancer Research</i> , 2020, 22, 57.	5.0	63
10	Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy—A Rare Event. <i>JAMA Oncology</i> , 2021, 7, 1851.	7.1	61
11	Safety and efficacy of radioactive seed localization with I-125 prior to lumpectomy and/or excisional biopsy. <i>European Journal of Radiology</i> , 2013, 82, 1453-1457.	2.6	60
12	Improving Access to Care: Breast Surgeons, the Gatekeepers to Breast Reconstruction. <i>Journal of the American College of Surgeons</i> , 2012, 214, 270-276.	0.5	43
13	Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 1912-1920.	1.5	37
14	Impact of Molecular Subtype on Locoregional Recurrence in Mastectomy Patients with T1-T2 Breast Cancer and 1-3 Positive Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2014, 21, 1569-1574.	1.5	34
15	The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy. <i>Annals of Surgical Oncology</i> , 2015, 22, 2517-2525.	1.5	29
16	Estimating the OncotypeDX score: validation of an inexpensive estimation tool. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 435-441.	2.5	22
17	Is Clinical Exam of the Axilla Sufficient to Select Node-Positive Patients Who Downstage After NAC for SLNB? A Comparison of the Accuracy of Clinical Exam Versus MRI. <i>Annals of Surgical Oncology</i> , 2019, 26, 4238-4243.	1.5	22
18	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. <i>Breast</i> , 2022, 63, 123-139.	2.2	22

#	ARTICLE	IF	CITATIONS
19	Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in 20011-Eligible Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 1617-1624.	1.5	20
20	Breast Cancer Risk Factors in Younger and Older Women. <i>Annals of Surgical Oncology</i> , 2009, 16, 96-99.	1.5	15
21	Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers?. <i>Cancer</i> , 2018, 124, 4314-4321.	4.1	14
22	Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers. <i>Annals of Surgical Oncology</i> , 2018, 25, 3858-3866.	1.5	7
23	Supervised machine learning model to predict oncotype DX risk category in patients over age 50. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 423-430.	2.5	6
24	Concordance Between 21-Gene Recurrence Scores in Multifocal or Multicentric Breast Carcinomas Differs by Age and Histologic Subtype. <i>Annals of Surgical Oncology</i> , 2021, 28, 4256-4262.	1.5	5
25	Predictors of Breast Cancer Development in Women with Atypical Ductal Hyperplasia and Atypical Lobular Hyperplasia. <i>Annals of Surgical Oncology</i> , 2011, 18, 463-467.	1.5	4
26	American trends in oncoplastic breast surgery for 2006â€“2015: A retrospective analysis of NSQIP database. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2021, 74, 644-710.	1.0	4
27	Abstract PD4-05: Axillary recurrence is a rare event in node-positive patients. treated with sentinel node biopsy alone after neoadjuvant chemotherapy: Results of a prospective study. , 2021, , .		3
28	Use of postmastectomy radiation therapy in the treatment of breast cancer. <i>Breast Cancer Management</i> , 2012, 1, 177-180.	0.2	2
29	Predicting Oncotype DX scores using clinicopathologic features: A report from the National Cancer Database.. <i>Journal of Clinical Oncology</i> , 2018, 36, 551-551.	1.6	2
30	Minimally Invasive Approach to Breast Cancer: Is Less Better?. <i>Annals of Surgical Oncology</i> , 2011, 18, 3021-3023.	1.5	1
31	ASO Author Reflections: Age Is an Important Determinant of Concordance Between 21-Gene Recurrence Scores in Multiple Ipsilateral Breast Carcinomas. <i>Annals of Surgical Oncology</i> , 2021, 28, 4263-4264.	1.5	1
32	SURGICAL ANATOMY OF THE BREAST. , 2012, , 1-12.		0
33	Does a positive sentinel lymph node always require completion dissection?. <i>Breast Cancer Management</i> , 2012, 1, 97-100.	0.2	0
34	SKIN INCISIONS. , 2012, , 57-63.		0
35	ONCOPLASTIC BREAST REDUCTION. , 2012, , 129-157.		0
36	Is breast reconstruction a quality measure for breast cancer treatment?. <i>Breast Cancer Management</i> , 2013, 2, 349-352.	0.2	0

#	ARTICLE	IF	CITATIONS
37	ASO Author Reflections: Locoregional Recurrence Rates are Low with the Selective Use of PMRT in Patients with T1-2 Tumors and One to Three Positive Lymph Nodes. Annals of Surgical Oncology, 2018, 25, 691-692.	1.5	0
38	Reply to Significance of 21-Gene Nonconcordant Recurrence Scores in Patients with Multifocal or Multicentric Breast Carcinomas. Annals of Surgical Oncology, 2021, 28, 793-794.	1.5	0
39	MASTOPEXY. , 2012, , 159-176.		0
40	REPAIR OF BREAST DEFECTS. , 2012, , 99-127.		0
41	NEOADJUVANT THERAPY. , 2012, , 27-56.		0
42	RESECTION OF THE TUMOR. , 2012, , 87-97.		0
43	SURGICAL LANDMARKS AND MEASUREMENTS. , 2012, , 13-26.		0
44	SKIN-SPARING MASTECTOMY. , 2012, , 177-191.		0
45	Postmastectomy Radiation. , 2019, , 215-220.		0
46	Glandular Displacement Techniques. , 2019, , 307-318.		0
47	Statistical machine learning model to predict Oncotype DX risk category in women over age 50.. Journal of Clinical Oncology, 2020, 38, 524-524.	1.6	0
48	Management of the axilla in T1-2N1 breast cancer. Npj Breast Cancer, 2022, 8, .	5.2	0